Greater market penetration and stronger sales of core dialysis-related products
First written in FY2016. 27 of 37 entries say "Restated". Latest entry: 2026-08-10.
2 other companies' latest entry also says "Advanced".
- 2026-08-10AdvancedEarnings
「Under these circumstances, we worked to further establish our flagship products, including Kindaly dialysis agents for artificial kidneys, other dialysis-related products and pharmaceuticals, and infusions, while also focusing on promoting sales of generic drugs. As a result, revenue for the first quarter increased by ¥543 million, or 3.5%, year on year to ¥16,046 million, despite the negative impact of the drug-price revision on generic-drug sales, due in part to the effectiveness of our sales-promotion activities.」
The company continued to expand sales of its core dialysis-related products and pharmaceuticals and infusions and disclosed revenue growth driven in part by the effectiveness of sales-promotion activities. - FY2026AdvancedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs. As a result, for the fiscal year, net sales increased by ¥1,744 million, or 2.9%, year on year to ¥62,307 million, due in part to promoting generic drugs related to renal and dialysis care.」
The company continued to expand market penetration of flagship dialysis-related products and infusion products and promote sales of generic drugs, resulting in a 2.9% year-on-year increase in full-year net sales. - FY2026-H1AdvancedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs. As a result, for the interim accounting period, net sales increased by ¥1,490 million, or 5.0%, year on year to ¥31,229 million, due in part to promoting generic drugs related to renal and dialysis care.」
The company continued to expand market penetration of flagship dialysis-related products and infusion products and promote sales of generic drugs, resulting in a 5.0% year-on-year increase in net sales. - FY2025AdvancedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs. As a result, for the fiscal year, net sales increased by ¥5,155 million, or 9.3%, year on year to ¥60,563 million, due in part to increased production and sales resulting from promoting generic drugs related to renal and dialysis care and alternative supply of infusion and injection products manufactured by other companies.」
Full-year net sales increased 9.3% year on year due to market penetration of flagship dialysis-related products and infusion products, promotion of generic drug sales, and alternative supply of infusion and injection products manufactured by other companies. - FY2025-H1AdvancedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs. As a result, for the interim accounting period, net sales increased by ¥2,314 million, or 8.4%, year on year to ¥29,739 million, due in part to increased sales from promoting generic drugs related to renal and dialysis care and increased production and sales resulting from alternative supply of infusion and injection products manufactured by other companies.」
As a result of continued market penetration of flagship dialysis-related products and infusion products and promotion of generic drug sales, including alternative supply of products manufactured by other companies, interim net sales increased 8.4% year on year. - FY2024RestatedAnnual report
「Accordingly, as a priority issue, we are making every effort to strengthen sales by further increasing market penetration, centered on our existing flagship products. To maintain our leading market share as a dialysis-product manufacturer, we are also working to further strengthen our business foundation by developing new dialysis products and expanding our product lineup, including generic drugs.」
The company continues to expand market penetration of its flagship products, maintain its leading market share, develop new dialysis products, and expand its product lineup. - FY2024-Q3RestatedAnnual report
「Under these circumstances, we worked to further establish our flagship products, including Kindaly dialysis agents for artificial kidneys, other dialysis-related products and pharmaceuticals, and infusions, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and strengthen sales of its flagship dialysis-related products and infusion products. - FY2024-Q2RestatedAnnual report
「Under these circumstances, we worked to further establish our flagship products, including Kindaly dialysis agents for artificial kidneys, other dialysis-related products and pharmaceuticals, and infusions, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and strengthen sales of its flagship dialysis-related products and infusion products. - FY2024-Q1RestatedAnnual report
「Under these circumstances, we worked to further establish our flagship products, including Kindaly dialysis agents for artificial kidneys, other dialysis-related products and pharmaceuticals, and infusions, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and promote sales of its flagship dialysis-related products and infusion products, as well as generic drugs. - FY2023-Q3RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and strengthen sales of products related to hemodialysis and infusion products. - FY2023-Q2RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and strengthen sales of its flagship dialysis-related products and infusion products. - FY2023-Q1RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and strengthen sales of its flagship dialysis-related products and infusion products. - FY2022RestatedAnnual report
「Accordingly, as a priority issue, we are making every effort to strengthen sales by further increasing market penetration, centered on our existing flagship products. To maintain our leading market share as a dialysis-product manufacturer, we are also working to further strengthen our business foundation by developing new dialysis products and expanding our product lineup, including generic drugs.」
The company continues to expand market penetration and strengthen sales of flagship products, maintain its leading market share, develop new dialysis products, and expand its product lineup. - FY2022-Q2RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration of its flagship dialysis-related products and infusion products and promote sales of generic drugs. - FY2021RestatedAnnual report
「Accordingly, as a priority issue, we are making every effort to strengthen sales by further increasing market penetration, centered on our existing flagship products. To maintain our leading market share as a dialysis-product manufacturer, we are also working to further strengthen our business foundation by developing new dialysis products and expanding our product lineup, including generic drugs.」
The company continues to expand market penetration and strengthen sales of flagship products, maintain its leading market share, develop new dialysis products, and expand its product lineup, including generic drugs. - FY2021-Q3RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration of its flagship dialysis-related products and infusion products and promote sales of generic drugs. - FY2021-Q2RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and strengthen sales of products related to hemodialysis and infusion products. - FY2021-Q1RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration of its flagship dialysis-related products and infusion products and promote sales of generic drugs. - FY2020RestatedAnnual report
「Accordingly, as a priority issue, we are making every effort to strengthen sales by further increasing market penetration, centered on our existing flagship products. To maintain our leading market share as a dialysis-product manufacturer, we are also working to further strengthen our business foundation by developing new dialysis products and expanding our product lineup, including generic drugs.」
The company continues its policy of expanding market penetration and strengthening sales of flagship products, and specifically describes maintaining its leading market share, developing new dialysis products, and expanding its lineup, including generic drugs, as measures. - FY2020-Q3RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to develop new demand markets and expand sales of products including dialysis solutions, replacement fluids, physiological saline, dialysis-related products, blood purification devices, and dialyzers. - FY2020-Q2RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and strengthen sales of products related to hemodialysis, infusion products, and generic drugs. - FY2020-Q1RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and strengthen sales of products related to hemodialysis, infusion products, and generic drugs. - FY2019RestatedAnnual report
「We have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration and strengthen sales of products related to hemodialysis and infusion products. - FY2019-Q3RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to develop new demand markets and expand sales of products including dialysis solutions, replacement fluids, physiological saline, dialysis-related products, blood purification devices, and dialyzers. - FY2019-Q2RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to develop new demand markets and expand sales of products including dialysis solutions, replacement fluids, physiological saline, dialysis-related products, blood purification devices, and dialyzers. - FY2019-Q1RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to develop new demand markets and expand sales of products including dialysis solutions, replacement fluids, physiological saline, dialysis-related products, blood purification devices, and dialyzers. - FY2018RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to strengthen market penetration and sales of dialysis-related products and infusion products. - FY2018-Q3RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration of products related to hemodialysis and infusion products. - FY2018-Q1RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to expand market penetration of products related to hemodialysis and infusion products. - FY2017RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to make the stable supply of dialysis products its top priority while developing new demand markets and expanding sales of related products. - FY2017-Q3RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to develop new demand markets and expand sales of related products, centered on dialysis solutions. - FY2017-Q2RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to develop new demand markets and expand sales of related products, centered on dialysis solutions. - FY2017-Q1RaisedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company has explicitly stated a sales policy of expanding its target products and demand markets beyond its flagship dialysis solutions to include replacement fluids, physiological saline, dialysis-related products, blood purification devices, and dialyzers. - FY2016First statedAnnual report
「In sales, we will make every effort to strengthen sales by further increasing market penetration, centered on our flagship products.」
The company explicitly identifies market penetration centered on its flagship products as a key sales priority.